Gilead announces approval of Biktarvy in Hong Kong

Gilead Sciences announced that the Hong Kong Department of Health has approved Biktarvy, a once-daily single tablet regimen, or STR, for the treatment of HIV-1 infection in adults. Hong Kong is the first market in Asia to approve Biktarvy. The triple-combination, single-tablet therapy combines the potency of the novel integrase strand transfer inhibitor, or INSTI, bictegravir, with the demonstrated safety and efficacy profile of a guideline recommended dual nucleoside reverse transcriptase inhibitor backbone – Descovy. BIC/FTC/TAF provides a convenient once-daily dosing STR without regards of food. Furthermore, BIC/FTC/TAF’s use is not restricted by the patient’s baseline viral load, CD4 cell count or HLA-B 5701 status.
https://thefly.com/landingPageNews.php?id=2798881